# A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

> **NCT02555306** · PHASE1,PHASE2 · COMPLETED · sponsor: **Santen Inc.** · enrollment: 12 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** 0.5 mg of DE-122
- **DRUG:** 1.0 mg of DE-122
- **DRUG:** 2.0 mg of DE-122
- **DRUG:** 4.0 mg of DE-122

## Key facts

- **NCT ID:** NCT02555306
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-16
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555306, "A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02555306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*